Financials

News Discussions Technicals Seasonals

222110 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

PanGen Biotech, Inc. engages in the production and sales of biopharmaceuticals. Its products include biosimilar erythropoietin (EPO), recombinant Factor VIII, biosimilar Aflibercept, recombinant anti-SFTSV Ab, and biosimilar G-CSF. The company was founded on January 29, 2010 and is headquartered in Suwon-si, South Korea.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

222110 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company